Abstract The coronavirus disease 2019 (COVID-19) pandemic is currently recognized as a
global health crisis. This viral infection is frequently associated with hypercoagulability, with …

Low molecular weight heparin, enoxaparin, has been one of most used drugs to fight the
SARS-CoV-2 pandemic. Pharmacological properties of heparin recognize its specific ability …

The severe coronavirus disease 2019 (COVID-19) is associated with coagulopathy.
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and …

Activation of blood coagulation and endothelial inflammation are hallmarks of respiratory
infections with RNA viruses that contribute significantly to the morbidity and mortality of …

Antithrombotic drugs are widely used for primary and secondary prevention, as well as
treatment of many cardiovascular disorders. Over the past few decades, major advances in …

Background Mortality in critically ill COVID-19 patients remains high. Although randomized
controlled trials must continue to definitively evaluate treatments, further hypothesis …

SARS-Cov-2 infection, a pandemic disease since March 2020, is associated with a high
percentage of cardiovascular complications mainly of a thromboembolic (TE) nature …

Purpose: Heparin-based regimens are recommended for anticoagulation in hospitalized
patients with COVID-19 though a study reported similar mortality with apixaban in critically ill …

Anticoagulants are associated with clinical benefit against the 2019 coronavirus disease
(COVID-19), preventing COVID-19 associated coagulopathy. Blood coagulation factor Xa …

The challenge of a previously unknown virus with unusual clinical impact, rise the interest of
clinicians and researchers facing multiple challenges. Direct viral damage in many cellular …